TACSTD2 and neoplasm: Sacituzumab govitecan (SG) is a Trop-2–directed antibody–drug conjugate that delivers SN-38 (the active metabolite of the topoisomerase inhibitor irinotecan) to tumor cells via internalization and to the surrounding tumor microenvironment via the bystander effect [9].